XML 61 R47.htm IDEA: XBRL DOCUMENT v3.21.1

Long-Term Investments (Details) - Schedule of long-term investment - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Non-marketable Cost Method Investments, net
Sub total	$ 909,436	$ 922,391
Equity Method Investments, net
Total	1,126,884	1,190,727
Braingenesis Biotechnology Co., Ltd. [Member]
Non-marketable Cost Method Investments, net
Sub total	7,742	7,853
Genepharm Biotech Corporation [Member]
Non-marketable Cost Method Investments, net
Sub total	23,638	23,974
BioHopeKing Corporation [Member]
Non-marketable Cost Method Investments, net
Sub total	878,056	890,564
BioFirst Corporation [Member]
Equity Method Investments, net
Total	217,448	268,336
Rgene Corporation [Member]
Equity Method Investments, net
Total

X

- References

No definition available.

+ Details

Name:	abvcd_EquityMethodInvestmentsNetAbstract
Namespace Prefix:	abvcd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	abvcd_NonMarketableCostMethodInvestmentsNetAbstract
Namespace Prefix:	abvcd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	abvcd_NonmarketableCostMethodInvestmentsNet
Namespace Prefix:	abvcd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_EquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BraingenesisBiotechnologyCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_GenepharmBiotechCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioHopeKingCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: